Phathom Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. (PHAT) filed a Current Report on Form 8-K on April 30, 2026. The filing announces the issuance of a press release detailing financial results for the quarter ended March 31, 2026. The company is incorporated in Delaware and trades on The Nasdaq Global Select Market.
Key Financial Metrics
The provided filing text serves as a cover document referencing an attached press release (Exhibit 99.1) for detailed financial data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reported period.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer under General Instruction B.2 of Form 8-K. It states that the information in this report, including the attached press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K form itself.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the attached exhibit.
- Confirm the status of any outstanding debt or financing arrangements referenced in the full press release.